Mumbai, Maharashtra, India- Business Wire India
The Board of Directors of Unichem Laboratories Ltd at their meeting held on July
12, 2014 approved the First Quarter (Q1) Un-audited Results for FY 2014-15.
The Company's standalone revenue from operations stood at Rs. 290.99 crs for the
quarter ended June 30, 2014 against Rs. 265.57 crs recorded during the
corresponding quarter of the previous year, reflecting a growth of 9.6%.
The Company's EBITDA for the quarter stood at Rs. 43.68 crs.
The Company recorded a Net Profit After Tax of Rs. 30.19 Crores for the quarter
ended June 30, 2014 as against Rs. 36.09 Crores in the corresponding quarter of
the previous year.
The EPS-Diluted for the current quarter stood at Rs. 3.32 (corresponding quarter
previous year: Rs. 3.98).
About Unichem Laboratories Limited
Unichem Laboratories Limited is an International, integrated, specialty
pharmaceutical Company. It manufactures and markets a large basket of
pharmaceutical formulations as branded generics as well as generics in India and
several other markets across the world. In India, the Company is a leaded in
niche areas of cardiology, neurology and other orthopedics and anti-infectives.
The Company has strong skills in product development, process chemistry and
manufacturing of complex API as well as dosage forms.
More information about the Company can be found at www.unichemlabs.com
Media Contact Details
Rakesh Parikh, Unichem Laboratories Limited, +91 (22) 66888414,
Monish Shah, Unichem Laboratories Limited, +91 (22) 66888509,
Contributed via: Bloomberg Publisher WEB Service
Provider ID: 457008ccea654cad93c56fb89696deb0
-0- Jul/14/2014 13:30 GMT
Press spacebar to pause and continue. Press esc to stop.